Helixmith Co. Ltd.

05/17/2022 | Press release | Distributed by Public on 05/17/2022 11:42

Helixmith Participated in 2022 Bio Korea, held May 11th - May 13th

본문

Bio Korea served as an opportunity for Helixmith to explore potential commercial partnerships based on the excellence and unique offerings of its Cell & Gene Therapy (CGT) plant, a GMP production facility for cell and gene therapy products.

Hosted by the Korea Health Industry Development Institute, Bio Korea is the largest bio industry convention in Korea, now in its 17thyear. The event draws biohealth executives, expert consultants, researchers, policy makers, and investors from around the world looking to share insights into the global biohealth industry landscape and technology development trends. Helixmith introduced the CGT plant to biopharmaceutical development companies aiming to develop cell gene therapy products. The cell and gene therapy production facility was established in September 2021 at Helixmith headquarters in Magok, Seoul. The CGT plant focuses on providing superior clinical samples at a global level, and offers services ranging from efficient manufacturing of cell and gene therapy products customized to client demand, to quality assurance backed by rigorous drug analysis. The distinguishing feature of the CGT plant is its ability to provide a comprehensive array of solutions across all fields, including manufacturing and provision of its own vectors, process development, and analysis technology development. Most notably, the CGT plant also functions as a one-stop shop, producing CAR-T products ready to enter into clinical trials with only a nucleotide sequence provided by the client. Helixmith CTO Seungshin Yu stated that, "As domestic and international demand for new drug development increases, the CDMO business for cell and gene therapy is expected to receive more attention. We plan to actively introduce technology and one-stop services for the development and production of unique cell and gene therapy products. In so doing, Helixmith will make significant contributions to the international competitiveness of high-tech domestic biopharmaceutical companies by solving the diverse needs of bio ventures."